Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry

PURPOSE: The monarchE trial showed that the addition of abemaciclib improves efficacy in patients with high-risk early breast cancer (EBC). We analyzed the long-term outcomes of a population similar to the monarchE trial to put into context the potential benefit of abemaciclib. METHODS: HR-positive/...

Descripción completa

Detalles Bibliográficos
Autores principales: Martín, Miguel, Carrasco, Eva, Rodríguez-Lescure, Álvaro, Andrés, Raquel, Servitja, Sonia, Antón, Antonio, Ruiz-Borrego, Manuel, Bermejo, Begoña, Guerrero, Ángel, Ramos, Manuel, Santaballa, Ana, Muñoz, Montserrat, Cruz, Josefina, Lopez-Tarruella, Sara, Chacón, Jose I., Álvarez, Isabel, Martínez, Purificación, Miralles, Juan J., Polonio, Óscar, Jara, Carlos, Aguiar-Bujanda, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361852/
https://www.ncbi.nlm.nih.gov/pubmed/37338729
http://dx.doi.org/10.1007/s10549-023-07002-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361852/
https://www.ncbi.nlm.nih.gov/pubmed/37338729
http://dx.doi.org/10.1007/s10549-023-07002-1

Ejemplares similares